Zantac is a popular over-the-counter and prescription heartburn medication that works by decreasing stomach acid production. Some samples of Zantac were found to contain a carcinogen called NDMA, prompting drug manufacturer Sanofi to pull the drug off of shelves. James F. Humphreys & Associates, L.C. is currently investigating Zantac cases because we believe you have a right to know the risks of pharmaceutical medications.
Zantac is a popular over-the-counter and prescription H2 (histamine-2) blocker, which is used to treat heartburn and indigestion. In 2019, Zantac was found to contain dangerous levels of NDMA, a cancer-causing compound. Research found that the NDMA in Zantac was likely formed when Ranitidine, the active ingredient in the medication, broke down over time, especially when the medication was exposed to high temperatures during transport or storage. Research also indicated that conditions in the human body may contribute to the formation of NDMA. In October 2019, Sanofi voluntarily recalled its Zantac 150 and Zantac 75 products. Many retailers had already removed the products from their shelves prior to the recall.
In April 2020, the FDA directed companies to immediately stop selling all forms of Zantac and told consumers to dispose of any remaining Zantac liquid or tablet medication. NDMA, the carcinogen found in Zantac, may cause a number of cancers. Cancers currently under investigation for links to Zantac include stomach, bladder, kidney, pancreatic and colon cancer.
If you or a loved one took Zantac by prescription or over-the-counter and has been diagnosed with stomach cancer, bladder cancer, kidney cancer, pancreatic cancer, colon cancer, prostate cancer (under age 65) or breast cancer, you may be entitled to compensation. At James F. Humphreys & Associates, L.C., we will investigate your claim and have the resources necessary to fight for your rights against big pharmaceutical companies. Contact us today for a free consultation.
Toll Free: +1 (877) 341-2595